HUTCHMED 和记黄埔医药（上海）医药有限公司

2009年7月29日，和黄医药宣布提前完成了HMPL-004治疗轻中度活动期溃疡性结肠炎的全球IIb期临床试验患者的招募。IIb期临床试验是为了进一步证实候选药物HMPL-004在较大样本的人群和不同剂量�

Chi-Med increases ownership of its Hutchison Healthcare joint venture to 100%

Newly Published China National Essential Medicines List Reference Prices No Overall Negative Impact on Chi-Med Prices

Chi-Med announces joint venture with The Hain Celestial Group to develop natural and organic consumer products in Asia

Chi-Med's Main Drugs Included in the New National Essential Medicines List

Interim Results for the Six Months Ended 30 June 2009

和黄医药提前完成了治疗溃疡性结肠炎的候选药物（HMPL-004）全球IIb期临床试验患者的招募

和黄医药宣布HMPL-004治疗克罗恩病的国际多中心II期临床试验结果

Notice of Announcement of 2009 Interim Results

Blocklisting Six Monthly Return

Results of Annual General Meeting

Director's Shareholding

2008 Annual Report and Notice of Annual General Meeting

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

Date of Annual General Meeting

Final Results for the year ended 31 December 2008

TR-1: Notification of major interests in shares

Notice of Announcement of 2008 Final Results

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn's Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

Holding in Company

Director's Shareholding

HMPL-002 Clinical Update

Blocklisting Six Monthly Return

和黄医药携手强生旗下的Ortho-McNeil-Janssen制药公司共同研究开发创新药物

Director's Shareholding

和黄医药与美国礼来再度牵手

和黄医药荣获2008美国胃肠病学会学术年会国际奖

Board Change

Interim Results for the Six Months Ended 30 June 2008

Drug R&D Division: New employee share option scheme in Hutchison MediPharma

Notice of 2008 Interim Results

Blocklisting Six Monthly Return

Director's Shareholding

Board Change

China Healthcare Division Chi-Med increases ownership of its Hutchison Healthcare joint venture

Expansion of Consumer Products division Sen launches in 125 Marionnaud beauty stores

Results of Annual General Meeting

Holding in Company

Annual Report 2007 and Notice of Annual General Meeting

Holding in Company

Preliminary Results for the year ended 31 December 2007

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate

Notice of 2007 Preliminary Results

Change in the Registered Office Address in the Cayman Islands

Strong growth in China Healthcare divisionStreamlining of product range set to further improve financial performance

Block Admission Return

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients

和黄医药与美国礼来签订新药研发战略合作协议